US EditionPublished • loading... • Updated
French Adcytherix raises €105 million for its next-generation antitumor drugs
Summary by Eurasia Business News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
French Adcytherix raises €105 million for its next-generation antitumor drugs
By John Meyer, consultant in business – Eurasia Business News, October 16, 2025. Article no. 1828 Adcytherix, a biopharmaceutical company based in Marseille, France, recently raised €30 million in seed funding to develop its next-generation antibody-drug conjugates (ADCs) for cancer treatment. Founded by Jack Elands and supported by Pontifax Venture Capital, the funding round was also backed by major life science investors including Pureos Biove…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
